ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Boehringer Ingelheim clinical trials

Also known as BI.

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,305 studies whose lead sponsor is Boehringer Ingelheim. 62 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Boehringer Ingelheim with Merck and Novo Nordisk →

Pipeline: 45 programs

Each counted once: 42 with a study Boehringer Ingelheim leads registered in the last two years, 3 more from Boehringer Ingelheim's own pipeline.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)
  • Named by Boehringer Ingelheim only (no registered study yet; not in the 45)

The 5 of 9 with the most live studies.

Program
obrixtamigPhase 3 · Boehringer Ingelheim: Phase 3 · 11 live · Small Cell Lung Carcinoma · primary completion Dec 2026☆ Track
survodutidePhase 3 · Boehringer Ingelheim: Phase 3 · 10 live · Obesity · primary completion Dec 2026☆ Track
nerandomilastPhase 3 · 7 live · Lung Diseases, Interstitial · primary completion Apr 2027☆ Track
verducatibPhase 3 · Boehringer Ingelheim: Phase 3 · 7 live · Bronchiectasis · primary completion Dec 2026☆ Track
zongertinibPhase 3 · 7 live · Lung Neoplasms · primary completion Dec 2026☆ Track

4 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Boehringer Ingelheim’s own registered studies; “Boehringer Ingelheim says” is its pipeline, which lists phases by indication. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Boehringer Ingelheim’s studies test, most open studies first — 252 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 252; every drug is on its own page, and each page lists its sponsors.

Coming up

46 of Boehringer Ingelheim’s studies under way reach primary completion within a year, 7 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 2N’26
  2. 13D
  3. 2J’27
  4. 3F
  5. 9M
  6. 4A
  7. M
  8. 4J
  9. 2J
  10. 4A
  11. S
  12. 3O
  13. N

The 12 nearest

Show 7 more

Add all 46 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 19, 2026.

All 2,305 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now623%Recruiting 49 · Not yet recruiting 13
  • Under way, not recruiting372%
  • Completed2,00487%
  • Stopped early1908%Terminated 155 · Withdrawn 31 · Suspended 4
  • Status unknown or other121%Approved for marketing 8 · No longer available 4

Phase

Where

Over the years

  1. 07
  2. 11508
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 6026

By the year each study started; 743 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Boehringer Ingelheim.

  • Boehringer Ingelheim
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2,305 studies

Focus areas

Conditions Boehringer Ingelheim leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Show all 32 areas

Studies

Recruiting first, then most recently updated. Showing 50 of 2,305. Browse all 2,305 →